Determining Prostate Cancer-Related Pathways and the Role of the RPH3AL Gene

Abstract

Objective: Prostate cancer is the fifth leading cause of death worldwide. Treatment modalities for advanced prostate cancer include androgen deprivation therapy (ADT), chemotherapy, radiotherapy, and targeted therapy. Transcriptomic profiling in prostate cancer enhances our understanding of the disease at the molecular level, facilitating more accurate diagnosis and personalized treatment choices, and ultimately improving patient outcomes. Identifying new therapeutic biomarkers for prostate cancer is important for developing targeted therapy options. This study aimed to elucidate the pathways associated with prostate cancer and identify differentially expressed genes. Materials and Methods: An RNA-seq dataset, GSE210205, was used to reveal transcriptomic differences between prostate cancer and benign prostate cell lines. GEO2R analysis, GSEA analysis, WebGestalt analysis, and GEPIA analyses were performed to generate differentially expressed genes, identify enriched pathways, and investigate gene expression in prostate cancer. Results: Pathways such as Wnt/β-catenin signaling, DNA IR-induced double-strand breaks, cellular response via ATM, Type II interferon signaling, and TGF-β signaling were enriched in the prostate cancer transcriptome. Among the five most over-expressed genes, RPH3AL was the most prominent. Conclusion: RPH3AL is a potential biomarker for prostate cancer based on transcriptomic profiling. Further investigation is required to validate the role and potential of this agent as a therapeutic target.

Keywords

• Prostate cancer
• transcriptomic profiling
• RPH3AL
• TGF-β

References

1. 1. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med 2018; 8(12): a030361. google scholar
2. 2. Kulasegaran T, Oliveira N. Metastatic castration-resistant prostate 19. cancer: Advances in treatment and symptom management. Curr Treat Options Oncol 2024; 25(7): 914-31. google scholar
3. 3. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer 20. treatment. CA Cancer J Clin 2008; 58(4): 196-213. google scholar
4. 4. Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in 21. prostate cancer. Urol Oncol-Semin Ori 2015; 33(2): 85-94. google scholar
5. 5. Matsumoto M, Miki T, Shibasaki T, Kawaguchi M, Shinozaki H, Nio J, et al. Noc2 is essential in normal regulation of exocytosis in endocrine and exocrine cells. Proc Natl Acad Sci U S A 2004; 101(22): 8313-8. 22. google scholar
6. 6. Guo YP. Understanding prostate cancer genetic susceptibility and chromatin regulation: University of Southern California, Doctoral Thesis. 2019. google scholar
7. 7. Wu Q, Zhou Y, Chen L, Shi J, Wang CY, Miao L, et al. Benign 23. prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2. J Endocrinol 2007; 195(1): 89-94. google scholar
8. 8. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. 24. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17(1):16-23. google scholar

9. 9. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978; 21(3): 274-81. google scholar
10. 10. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15(12): 550. google scholar
11. 11. Alhamdoosh M, Law CW, Tian L, Sheridan JM, Ng M, Ritchie ME. Easy and efficient ensemble gene set testing with EGSEA. 27. F1000Res 2017; 6: 2010. google scholar
12. 12. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45(W1): W98-W102. google scholar
13. 13. Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol 2012; 9(8): 418-28. google scholar
14. 14. Wang C, Chen Q, Xu H. Wnt/beta-catenin signal transduction pathway in prostate cancer and associated drug resistance. Discov Oncol 2021; 12(1): 40. google scholar
15. 15. Shibata A, Jeggo PA. ATM’s role in the repair of dna double-strand breaks. Genes (Basel) 2021; 12(9): 1370. google scholar
16. 16. Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl 2012; 14(3): 409-14. google scholar
17. 17. Fenton SE, Saleiro D, Platanias LC. Type I and II interferons in the anti-tumor immune response. Cancers (Basel) 2021; 13(5): 1037. google scholar
18. 18. Hastie C. Interferon gamma, a possible therapeutic approach for late-stage prostate cancer? Anticancer Res 2008; 28(5B): 2843-9. google scholar
19. 19. Hagiwara M, Fushimi A, Bhattacharya A, Yamashita N, Morimoto Y, Oya M, et al. MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology 2022; 11(1): 2029298. google scholar
20. 20. Guo W, Liu H, Yan Y, Wu D, Yao H, Lin K, et al. Targeting the TGF-beta signaling pathway: an updated patent review (2021-present). Expert Opin Ther Pat 2024; 34(3): 99-126. google scholar
21. 21. Eisenhofer G, Huynh TT, Elkahloun A, Morris JC, Bratslavsky G, Linehan WM, et al. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. Am J Physiol Endocrinol Metab 2008; 295(5): E1223-33. google scholar
22. 22. Smith JS, Tachibana I, Allen C, Chiappa SA, Lee HK, McIver B, et al. Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus. Genomics 1999; 59(1): 97-101. google scholar
23. 23. Lv L, Zhang D, Hua P, Yang S. The glial-specific hypermethylated 3 untranslated region of histone deacetylase 1 may modulates several signal pathways in Alzheimer’s disease. Life Sciences 2021; 265: 118760. google scholar
24. 24. Martı'nez Arroyo O. Insights into the role of the RAB3A-RAB27A system on the development of kidney injury associated with type II diabetes mellitus. University of Valencia, Doctoral Thesis. 2024. google scholar
25. 25. Chipidza FE, Alshalalfa M, Mahal BA, Karnes RJ, Liu Y, Davicioni E, et al. Development and validation of a novel TP53 mutation signature that predicts risk of metastasis in primary prostate cancer. Clin Genitourin Cancer 2021; 19(3): 246-54.e5. google scholar
26. 26. Putcha BD, Jia X, Katkoori VR, Salih C, Shanmugam C, Jadhav T, et al. Clinical implications of Rabphillin-3A-Like gene alterations in breast cancer. PLoS One 2015; 10(6): e0129216. google scholar
27. 27. Chen JS, Kuo YB, Chou YP, Chan CC, Fan CW, Chen KT, et al. Detection of autoantibodies against Rabphilin-3A-like protein as a potential biomarker in patient’s sera of colorectal cancer. Clin Chim Acta 2011; 412(15-16): 1417-22. google scholar
28. 28. Shibasaki T, Seino S. Physical and functional interaction of noc2/ rab3 in exocytosis. Methods Enzymol 2005; 403: 408-19. google scholar